Ludwig Institute For Cancer Research Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Ludwig Institute For Cancer Research Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137989D
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ludwig Institute for Cancer Research Ltd (LICR) is a non-profit organization that conducts cancer research and clinical trial programs. The organization carries out research in the areas of clinical trials, genomics, cell biology, immunology, neuroscience, signaling, therapeutics, stem cells and tumor biology, among others. It provides patents, licensing, contracts, portfolio development, clinical trials and start up biotech services, among others. LICR develops cancer vaccines, targeted antibodies, enzymatic depletion, small molecule inhibitors, siRNAs, and others. The organization has partnership with various institutions. It has operations in Baltimore, Boston, Brussels, Chicago, Lausanne, Mebourne, New York, San Diego, and others. LICR is headquartered in New York, the US.

Ludwig Institute For Cancer Research Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

iTeos Therapeutics Raises USD 4 Million In Series A Financing 10

Partnerships 12

Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 12

Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 13

4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 15

Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 16

Licensing Agreements 18

iOx Therapeutics Enters into Licensing Agreement with Ludwig Institute 18

Agenus Enters into Licensing Agreement with Ludwig Institute 19

iTeos Therapeutics Receives Rights to IDO1 and TDO2 from Ludwig Institute for Cancer Research 20

Ludwig Institute For Cancer Research Ltd-Key Competitors 21

Ludwig Institute For Cancer Research Ltd-Key Employees 22

Ludwig Institute For Cancer Research Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 25

Government and Public Interest 25

Mar 15, 2018: Ludwig study extends the potential for personalized immunotherapy to a large variety of cancers 25

Jan 29, 2018: Ludwig researchers devise and test novel combination therapy for advanced melanoma 27

Nov 23, 2017: Ludwig Researchers Unravel Novel Mechanism By Which Tumors Grow Resistant To Radiotherapy 28

Sep 19, 2017: Ludwig Scientists Discover Complex Axis Of Immune Suppression Exploited By Cancers 29

Jun 22, 2017: Presence of protein important clue to tumour regression in neuroblastoma 31

Jun 22, 2017: The presence of the protein KIF1B? can play a central role for the outcome of a neuroblastoma diagnosis 32

May 12, 2017: Ludwig researchers identify counterintuitive approach to treating a brain cancer 33

Jan 16, 2017: Ludwig Study Reveals Why Cancer Cells Spread Within The Body 34

Product News 36

Dec 19, 2017: Ludwig Researchers Uncover Mechanism Behind a Metabolic Vulnerability of Certain Breast Cancers 36

Nov 10, 2017: Ludwig Researchers Uncover Novel Mechanism by Which Tumors Evade a Variety of Cancer Immunotherapies 38

Mar 15, 2017: Immunotherapy may help treat kids' brain tumors, preliminary Stanford study shows 40

Mar 02, 2017: A Vulnerability in Triple-negative Breast Cancer Could Improve Treatment Outcomes 41

Other Significant Developments 43

Mar 20, 2018: Six discoveries that greatly improved the treatment of ovarian cancer 43

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Figures

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ludwig Institute For Cancer Research Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Ludwig Institute For Cancer Research Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

iTeos Therapeutics Raises USD 4 Million In Series A Financing 10

Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 12

Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 13

4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 15

Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 16

iOx Therapeutics Enters into Licensing Agreement with Ludwig Institute 18

Agenus Enters into Licensing Agreement with Ludwig Institute 19

iTeos Therapeutics Receives Rights to IDO1 and TDO2 from Ludwig Institute for Cancer Research 20

Ludwig Institute For Cancer Research Ltd, Key Competitors 21

Ludwig Institute For Cancer Research Ltd, Key Employees 22

Ludwig Institute For Cancer Research Ltd, Other Locations 23

Ludwig Institute For Cancer Research Ltd, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Ludwig Institute For Cancer Research Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com